APA (7th ed.) Citation

Larkins, E., Blumenthal, G. M., Yuan, W., He, K., Sridhara, R., Subramaniam, S., . . . Pazdur, R. (2017). FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy. The oncologist (Dayton, Ohio), 22(7), 873-878. https://doi.org/10.1634/theoncologist.2016-0496

Chicago Style (17th ed.) Citation

Larkins, Erin, et al. "FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy." The Oncologist (Dayton, Ohio) 22, no. 7 (2017): 873-878. https://doi.org/10.1634/theoncologist.2016-0496.

MLA (9th ed.) Citation

Larkins, Erin, et al. "FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy." The Oncologist (Dayton, Ohio), vol. 22, no. 7, 2017, pp. 873-878, https://doi.org/10.1634/theoncologist.2016-0496.